Welcome to our dedicated page for Estrella Immunopharma news (Ticker: UPTDU), a resource for investors and traders seeking the latest updates and insights on Estrella Immunopharma stock.
Estrella Immunopharma, Inc. (UPTDU) is a clinical-stage biopharmaceutical company pioneering ARTEMIS T-cell therapies for blood cancers and solid tumors. This page serves as the definitive source for verified updates on the company's scientific advancements, strategic partnerships, and regulatory developments.
Investors and researchers will find comprehensive coverage of key initiatives including the anti-CD19 therapy EB103, dual-target EB104 program, and collaborative oncolytic virus research with Imugene Limited. All content is curated to meet stringent compliance standards while maintaining scientific accuracy.
Our news collection focuses on three core areas: clinical trial milestones, intellectual property developments, and executive leadership updates. Regular updates ensure stakeholders stay informed about manufacturing partnerships, research publications, and financial positioning without speculative commentary.
Bookmark this page for real-time updates on Estrella's mission to advance next-generation immunotherapies. For complete investment information, always consult official SEC filings and clinical trial registries.
TradeUP Acquisition Corp. (NASDAQ: UPTDU) announced that starting September 7, 2021, holders of its Units can separately trade the included common stock and warrants. The Units, initially sold in an IPO, will continue to trade under the symbol 'UPTDU.' The underlying common stock and warrants will trade under 'UPTD' and 'UPTDW,' respectively. This separation process requires holders to contact VStock Transfer, LLC. US Tiger Securities, Inc. was the lead manager of the IPO, which became effective on July 14, 2021.
TradeUp Acquisition Corp. (NASDAQ: UPTDU) has successfully closed its initial public offering (IPO), raising $44.3 million through the issuance of 4,430,000 units at $10.00 per unit. The offering, which included 430,000 units from an over-allotment option, commenced trading on the NASDAQ on July 15, 2021. Each unit comprises one common stock share and half a redeemable warrant, with warrants exercisable at $11.50 per share. The company is a blank check firm targeting potential mergers, primarily in the technology sector.
TradeUp Acquisition Corp. (NASDAQ: UPTDU) has priced its initial public offering (IPO) of 4,000,000 units at $10.00 each, set to trade on NASDAQ under the ticker symbol UPTDU from July 15, 2021. Each unit consists of one share of common stock and half a redeemable warrant, with each whole warrant exercisable at $11.50 per share. The company has granted underwriters a 45-day option to purchase an additional 600,000 units. The offering is expected to close on July 19, 2021.
